Psilocybin is under clinical development by Compass Pathways and currently in Phase II for Body Dysmorphic Disorder. According to GlobalData, Phase II drugs for Body Dysmorphic Disorder does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Psilocybin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Psilocybin is under development for the treatment of treatment-resistant depressive disorder (P-TRD), autism, anorexia nervosa and body dysmorphic disorder. It is formulated as the capsule and administered by oral route. The drug candidate is a tryptamine alkaloid which is a psychedelic prodrug compound acts by targeting 5hydroxy tryptamine 1A and 2A.
The drug candidate was under development for the treatment of major deprresive disorder (MDD).
Compass Pathways overview
Compass Pathways (Compass) is a mental health care company. It focuses on developing psilocybin therapies for treatment-resistant depression, post-traumatic stress disorder and anorexia nervosa. The company is investigating a novel therapy based on its proprietary formulation of synthetic psilocybin, COMP360 in phase IIb clinical studies. The company operates offices in New York, the US. Compass is headquartered in Altrincham, Cheshire, the United Kingdom.
For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.